-transparent.png){kind=logo}
The object of this study was to establish the most effective regimen of cefodizime (CDZM) for patients with chronic renal failure undergoing hemodialysis (HD). T 1/2 beta of CDZM upon 1 g intravenous administration was 3.50 +/- 0.72 hours in an on-HD group, and it was 11.26 +/- 3.89 hours in an off-HD group. When CDZM was administered consecutively at a dose of 1 g or 2 g only after HD, the serum concentration of CDZM was maintained at levels sufficient to exert antibacterial activity, and no tendency for accumulation was observed. The most effective regimen of CDZM to HD patients, therefore, has been that in which concluded to administration was done only after completion of HD, in a dose of 1 g for mild infections and that of 2 g for severe infections.
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
January 1982,
Methods and findings in experimental and clinical pharmacology,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
September 1979,
International journal of clinical pharmacology and biopharmacy,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
August 1979,
International journal of clinical pharmacology and biopharmacy,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
July 1991,
Journal of clinical pharmacology,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
January 1983,
Nephron,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
October 1986,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
April 2017,
Hemodialysis international. International Symposium on Home Hemodialysis,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
December 1991,
Minerva medica,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
January 2004,
European journal of drug metabolism and pharmacokinetics,
N Itagaki, and
H Hasegawa, and
M Sakaguchi, and
T Oono, and
I Iwamoto, and
H Horiuchi, and
M Tsujino, and
K Takahashi, and
A Imada, and
A Horiuchi
April 1975,
The American journal of medicine,
